Review



anti endostatin  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems anti endostatin
    Anti Endostatin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti endostatin/product/R&D Systems
    Average 93 stars, based on 24 article reviews
    anti endostatin - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    anti endostatin  (R&D Systems)
    93
    R&D Systems anti endostatin
    Anti Endostatin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti endostatin/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    anti endostatin - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    rh-endostatin  (Simcere Pharmaceutical Group)
    90
    Simcere Pharmaceutical Group rh-endostatin
    Rh Endostatin, supplied by Simcere Pharmaceutical Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rh-endostatin/product/Simcere Pharmaceutical Group
    Average 90 stars, based on 1 article reviews
    rh-endostatin - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    intratumoral injection of recombinant human endostatin combined with chemotherapy  (Simcere Pharmaceutical Group)
    90
    Simcere Pharmaceutical Group intratumoral injection of recombinant human endostatin combined with chemotherapy
    The efficacy assessment of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based <t>chemotherapy</t>
    Intratumoral Injection Of Recombinant Human Endostatin Combined With Chemotherapy, supplied by Simcere Pharmaceutical Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/intratumoral injection of recombinant human endostatin combined with chemotherapy/product/Simcere Pharmaceutical Group
    Average 90 stars, based on 1 article reviews
    intratumoral injection of recombinant human endostatin combined with chemotherapy - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    endostatin (es)  (Simcere Pharmaceutical Group)
    90
    Simcere Pharmaceutical Group endostatin (es)
    The efficacy assessment of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based <t>chemotherapy</t>
    Endostatin (Es), supplied by Simcere Pharmaceutical Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/endostatin (es)/product/Simcere Pharmaceutical Group
    Average 90 stars, based on 1 article reviews
    endostatin (es) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    human endostatin elisa kit ehcol18a1  (Thermo Fisher)
    90
    Thermo Fisher human endostatin elisa kit ehcol18a1
    The efficacy assessment of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based <t>chemotherapy</t>
    Human Endostatin Elisa Kit Ehcol18a1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human endostatin elisa kit ehcol18a1/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    human endostatin elisa kit ehcol18a1 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    recombinant human endostatin rh-endostatin  (Simcere Pharmaceutical Group)
    90
    Simcere Pharmaceutical Group recombinant human endostatin rh-endostatin
    The efficacy assessment of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based <t>chemotherapy</t>
    Recombinant Human Endostatin Rh Endostatin, supplied by Simcere Pharmaceutical Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human endostatin rh-endostatin/product/Simcere Pharmaceutical Group
    Average 90 stars, based on 1 article reviews
    recombinant human endostatin rh-endostatin - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    elisa detection kit  (Cusabio)
    92
    Cusabio elisa detection kit
    A Fluorescence intensity at various time points following <t>iMSC</t> <t>Endostatin</t> recognition of tumors. B The endostatin-mCherry released by iMSC Endostatin at different time points was detected by a microplate reader. C The microplate reader was utilized to detect the total amount of endostatin-mCherry accumulated every four hours following full activation of iMSC Endostatin . D The amount of released endostatin by iMSC Endostatin was quantified using <t>ELISA</t> detection.
    Elisa Detection Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elisa detection kit/product/Cusabio
    Average 92 stars, based on 1 article reviews
    elisa detection kit - by Bioz Stars, 2026-03
    92/100 stars
    		  Buy from Supplier
    plasmid phr-gal4/uas-endostatin-ires-mcherry-pgk-bfp  (Affibody)
    90
    Affibody plasmid phr-gal4/uas-endostatin-ires-mcherry-pgk-bfp
    A Fluorescence intensity at various time points following <t>iMSC</t> <t>Endostatin</t> recognition of tumors. B The endostatin-mCherry released by iMSC Endostatin at different time points was detected by a microplate reader. C The microplate reader was utilized to detect the total amount of endostatin-mCherry accumulated every four hours following full activation of iMSC Endostatin . D The amount of released endostatin by iMSC Endostatin was quantified using <t>ELISA</t> detection.
    Plasmid Phr Gal4/Uas Endostatin Ires Mcherry Pgk Bfp, supplied by Affibody, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasmid phr-gal4/uas-endostatin-ires-mcherry-pgk-bfp/product/Affibody
    Average 90 stars, based on 1 article reviews
    plasmid phr-gal4/uas-endostatin-ires-mcherry-pgk-bfp - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    elisas measure tnf-α, g-csf, pdgf-bb, sdf-1, vegf, thrombospondin-1, thrombospondin-2 endostatin  (R&D Systems)
    90
    R&D Systems elisas measure tnf-α, g-csf, pdgf-bb, sdf-1, vegf, thrombospondin-1, thrombospondin-2 endostatin
    A Fluorescence intensity at various time points following <t>iMSC</t> <t>Endostatin</t> recognition of tumors. B The endostatin-mCherry released by iMSC Endostatin at different time points was detected by a microplate reader. C The microplate reader was utilized to detect the total amount of endostatin-mCherry accumulated every four hours following full activation of iMSC Endostatin . D The amount of released endostatin by iMSC Endostatin was quantified using <t>ELISA</t> detection.
    Elisas Measure Tnf α, G Csf, Pdgf Bb, Sdf 1, Vegf, Thrombospondin 1, Thrombospondin 2 Endostatin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elisas measure tnf-α, g-csf, pdgf-bb, sdf-1, vegf, thrombospondin-1, thrombospondin-2 endostatin/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    elisas measure tnf-α, g-csf, pdgf-bb, sdf-1, vegf, thrombospondin-1, thrombospondin-2 endostatin - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The efficacy assessment of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based chemotherapy

    Journal: World Journal of Surgical Oncology

    Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

    doi: 10.1186/s12957-024-03644-7

    Figure Lengend Snippet: The efficacy assessment of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based chemotherapy

    Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

    Techniques:

    The progression-free survival rate of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based chemotherapy

    Journal: World Journal of Surgical Oncology

    Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

    doi: 10.1186/s12957-024-03644-7

    Figure Lengend Snippet: The progression-free survival rate of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based chemotherapy

    Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

    Techniques:

    The overall survival rate of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based chemotherapy

    Journal: World Journal of Surgical Oncology

    Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

    doi: 10.1186/s12957-024-03644-7

    Figure Lengend Snippet: The overall survival rate of 154 cases of recurrent/metastatic head and neck squamous cell carcinoma patients treated with first-line PD-1 inhibitors in combination with a taxane-based chemotherapy

    Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

    Techniques:

    Kaplan-meier curves for univariate analysis of clinical characteristics in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with pd-1 inhibitors in combination with a taxane-based chemotherapy. Note (A) : Comparison of PFS survival curves based on the presence or absence of distant metastasis; (B) : Comparison of OS survival curves based on the presence or absence of distant metastasis; (C) : Comparison of PFS survival curves based on whether subsequent radiotherapy was administered; (D) : Comparison of OS survival curves based on whether subsequent radiotherapy was administered; (E): Comparison of PFS survival curves based on whether radiotherapy was administered before recurrence/metastasis; (F) : Comparison of OS survival curves based on whether radiotherapy was administered before recurrence/metastasis;

    Journal: World Journal of Surgical Oncology

    Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

    doi: 10.1186/s12957-024-03644-7

    Figure Lengend Snippet: Kaplan-meier curves for univariate analysis of clinical characteristics in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with pd-1 inhibitors in combination with a taxane-based chemotherapy. Note (A) : Comparison of PFS survival curves based on the presence or absence of distant metastasis; (B) : Comparison of OS survival curves based on the presence or absence of distant metastasis; (C) : Comparison of PFS survival curves based on whether subsequent radiotherapy was administered; (D) : Comparison of OS survival curves based on whether subsequent radiotherapy was administered; (E): Comparison of PFS survival curves based on whether radiotherapy was administered before recurrence/metastasis; (F) : Comparison of OS survival curves based on whether radiotherapy was administered before recurrence/metastasis;

    Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

    Techniques: Comparison

    Multifactorial analysis of progression-free survival in 154 cases of recurrent/metastatic squamous cell carcinoma of the head and neck treated with first-line pd-1 inhibitors combined with a taxane-based chemotherapy

    Journal: World Journal of Surgical Oncology

    Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

    doi: 10.1186/s12957-024-03644-7

    Figure Lengend Snippet: Multifactorial analysis of progression-free survival in 154 cases of recurrent/metastatic squamous cell carcinoma of the head and neck treated with first-line pd-1 inhibitors combined with a taxane-based chemotherapy

    Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

    Techniques:

    Multifactorial analysis of overall survival in 154 cases of recurrent/metastatic squamous cell carcinoma of the head and neck treated with first-line pd-1 inhibitors combined with a taxane-based chemotherapy

    Journal: World Journal of Surgical Oncology

    Article Title: The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

    doi: 10.1186/s12957-024-03644-7

    Figure Lengend Snippet: Multifactorial analysis of overall survival in 154 cases of recurrent/metastatic squamous cell carcinoma of the head and neck treated with first-line pd-1 inhibitors combined with a taxane-based chemotherapy

    Article Snippet: China International Medical Exchange Foundation, Simcere Anti-Tumor Special Fund Clinical Project, Intratumoral Injection of Recombinant Human Endostatin Combined with Chemotherapy for the Treatment of Exophytic Recurrent and Metastatic Malignant Tumors of the Head and Neck, Registration Number: ChiCTR1900022364; Project Number: Z-2014-06-18384.

    Techniques:

    A Fluorescence intensity at various time points following iMSC Endostatin recognition of tumors. B The endostatin-mCherry released by iMSC Endostatin at different time points was detected by a microplate reader. C The microplate reader was utilized to detect the total amount of endostatin-mCherry accumulated every four hours following full activation of iMSC Endostatin . D The amount of released endostatin by iMSC Endostatin was quantified using ELISA detection.

    Journal: Cell Death & Disease

    Article Title: Intelligent drugs based on notch protein remodeling: a defensive targeting strategy for tumor therapy

    doi: 10.1038/s41419-024-07008-7

    Figure Lengend Snippet: A Fluorescence intensity at various time points following iMSC Endostatin recognition of tumors. B The endostatin-mCherry released by iMSC Endostatin at different time points was detected by a microplate reader. C The microplate reader was utilized to detect the total amount of endostatin-mCherry accumulated every four hours following full activation of iMSC Endostatin . D The amount of released endostatin by iMSC Endostatin was quantified using ELISA detection.

    Article Snippet: ELISA: MSCs or iMSC Endostatin will be co-cultured with Skov3-GFP for 48 h, and MSCs and iMSC Endostatin cells will be sorted by flow cytometry and cultured in a 24-well plate coated with fibronectin for 24 h. The content of endostatin will be detected using an ELISA detection kit (CSB-E07973h; CUSABIO).

    Techniques: Fluorescence, Activation Assay, Enzyme-linked Immunosorbent Assay